Ultragenyx licenses US rights to long-chain fatty acid oxidation disorder drug
This article was originally published in Scrip
Executive Summary
Ultragenyx Pharmaceutical has licensed from the Baylor Research Institute in Dallas, Texas, the rights to triheptanoin (also known as UX007), an investigational treatment for long-chain fatty acid oxidation disorders (FAOD).